A real-world study of TACE combined with regorafenib as a second-line treatment for advanced hepatocellular carcinoma.
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pe16144-e16144, 1p
- Subject
- Language
- ISSN
- 0732183X